Symptoms of fatigue are often reported by patients in both the acute and chronic stages of recovery following a stroke. It is commonly associated with low mood and sleep disturbances, but can arise in their absence. However, it has also been associated with poorer long-term outcome and, as such, its aetiology warrants a greater understanding. There is convincing evidence that inflammatory cascades and cytokine signalling precipitated by the infarct promote fatigue, and these pathways may harbour therapeutic targets in its management. 1. Introduction The repercussions of stroke can be devastating, given that it can suddenly and permanently impair some of the most basic functions we all take for granted, including our mobility, speech, and effective swallowing [1]. A national campaign by The Stroke Association [2], termed “Act F.A.S.T.”, has recently promoted the swift presentation to healthcare services for any patient suspected of having acute stroke, with assessment for possible early thrombolysis. Gold standard care in hospital involves admission to a designated stroke unit. Here, a battery of investigations are performed to maximise secondary prevention, and a multidisciplinary team is able to coordinate timely rehabilitation and attention to ongoing medical, nutritional, and psychological needs. Amongst the risks of developing anxiety states and disorders of (usually low) mood, there exists a frequently occurring symptom of poststroke fatigue (PSF) which can blight stroke patients’ recovery long after their physical disabilities have resolved. Within the nervous system, fatigue can be centrally or peripherally mediated [3]. The latter, for instance, is seen in neuromuscular junction disorders, such as myasthenia gravis, and does have definable parameters as a clinical sign—these being diminished postexertional muscle power on the Medical Research Council (MRC) scale and a 10% decrement of motor end-plate potentials on electromyography recordings. However, central fatigue is not so easily defined and symptomatically lies on a continuous spectrum encompassing a whole host of fluid terms including vitality, motivation, and mood. It has been described in multiple sclerosis patients as “a subjective lack of physical and/or mental energy that is perceived by the individual or caregiver to interfere with usual or desired activities” [4] and is thus, by virtue of its own broad definition, a rather idiosyncratic experience open to personal interpretation. This is reflected by the large number of assessment scales or scoring systems for fatigue to be found
References
[1]
A. W. Barritt and D. G. Smithard, “Role of cerebral cortex plasticity in the recovery of swallowing function following dysphagic stroke,” Dysphagia, vol. 24, no. 1, pp. 83–90, 2009.
[2]
The Stroke Association, 2008, http://www.stroke.org.uk/.
[3]
F. Cantor, “Central and peripheral fatigue: exemplified by multiple scleosis and myasthenia gravis,” PM and R, vol. 2, no. 5, pp. 399–405, 2010.
[4]
Multiple Sclerosis Council for Clinical Practice Guidelines, “Fatigue and multiple sclerosis: evidence-based managements strategies for fatigue in multiple sclerosis,” Paralysed Veterans of America, 1998.
[5]
D. Claros-Salinas, D. Bratzke, G. Greitemann, N. Nickisch, L. Ochs, and H. Schr？ter, “Fatigue-related diurnal variations of cognitive performance in multiple sclerosis and stroke patients,” Journal of the Neurological Sciences, vol. 295, no. 1-2, pp. 75–81, 2010.
[6]
B. Y. Tseng and P. Kluding, “The relationship between fatigue, aerobic fitness, and motor control in people with chronic stroke: a pilot study,” Journal of Geriatric Physical Therapy, vol. 32, no. 3, pp. 97–102, 2009.
[7]
A. M. E. E. Zedlitz, L. Fasotti, and A. C. H. Geurts, “Post-stroke fatigue: a treatment protocol that is being evaluated,” Clinical Rehabilitation, vol. 25, no. 6, pp. 487–500, 2011.
[8]
S. Choi-Kwon, J. Choi, S. U. Kwon, D. W. Kang, and J. S. Kim, “Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study,” Cerebrovascular Diseases, vol. 23, no. 2-3, pp. 103–108, 2007.
[9]
A. Sterr, K. Herron, D. J. Dijk, and J. Ellis, “Time to wake-up: sleep problems and daytime sleepiness in long-term stroke survivors,” Brain Injury, vol. 22, no. 7-8, pp. 575–579, 2008.
[10]
G. E. Mead, C. Graham, P. Dorman et al., “Fatigue after stroke: baseline predictors and influence on survival. analysis of data from UK patients recruited in the international stroke trial,” PLoS One, vol. 6, no. 3, pp. 1–17, 2011.
[11]
F. McKechnie, S. Lewis, and G. Mead, “A pilot observational study of the association between fatigue after stroke and C-reactive protein,” Journal of the Royal College of Physicians of Edinburgh, vol. 40, no. 1, pp. 9–12, 2010.
[12]
L. Snaphaan, S. van der Werf, and F. -E. de Leeuw, “Time course and risk factors of post-stroke fatigue: a prospective cohort study,” European Journal of Neurology, vol. 18, no. 4, pp. 611–617, 2011.
[13]
J. Y. Park, M. H. Chun, S. H. Kang, J. A. Lee, B. R. Kim, and M. J. Shin, “Functional outcome in poststroke patients with or without fatigue,” The American Journal of Physical Medicine and Rehabilitation, vol. 88, no. 7, pp. 554–558, 2009.
[14]
W. K. Tang, Y. K. Chen, V. Mok et al., “Acute basal ganglia infarcts in poststroke fatigue: an MRI study,” Journal of Neurology, vol. 257, no. 2, pp. 178–182, 2010.
[15]
A. Lerdal, L. N. Bakken, E. F. Rasmussen et al., “Physical impairment, depressive symptoms and pre-stroke fatigue are related to fatigue in the acute phase after stroke,” Disability and Rehabilitation, vol. 33, no. 4, pp. 334–342, 2011.
[16]
J. A. Harbison, S. Walsh, and R. A. Kenny, “Hypertension and daytime hypotension found on ambulatory blood pressure is associated with fatigue following stroke and TIA,” QJM, vol. 102, no. 2, pp. 109–115, 2009.
[17]
C. Pellicano, A. Gallo, X. Li et al., “Relationship of cortical atrophy to fatigue in patients with multiple sclerosis,” Archives of Neurology, vol. 67, no. 4, pp. 447–453, 2010.
[18]
F. Staub and J. Bogousslavsky, “Fatigue after stroke: a major but neglected issue,” Cerebrovascular Diseases, vol. 12, no. 2, pp. 75–81, 2001.
[19]
J. Roding, B. Lindstr？m, J. Malm, and A. ？hman, “Frustrated and invisible—younger stroke patients' experiences of the rehabilitation process,” Disability and Rehabilitation, vol. 25, no. 15, pp. 867–874, 2003.
[20]
G. E. Carlsson, A. M？ller, and C. Blomstrand, “A qualitative study of the consequences of “hidden dysfunctions“ one year after a mild stroke in person < 75 years,” Disability and Rehabilitation, vol. 26, no. 23, pp. 1373–1380, 2004.
[21]
P. Appelros, “Prevalence and predictors of pain and fatigue after stroke: a population-based study,” International Journal of Rehabilitation Research, vol. 29, no. 4, pp. 329–333, 2006.
[22]
E. L. Glader, B. Stegmayr, and K. Asplund, “Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden,” Stroke, vol. 33, no. 5, pp. 1327–1333, 2002.
[23]
A. Lerdal, L. N. Bakken, S. E. Kouwenhoven et al., “Poststroke fatigue—a review,” Journal of Pain and Symptom Management, vol. 38, no. 6, pp. 928–949, 2009.
[24]
N. J. Rothwell, G. Luheshi, and S. Toulmond, “Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology,” Pharmacology and Therapeutics, vol. 69, no. 2, pp. 85–95, 1996.
[25]
L. Capuron and A. H. Miller, “Immune to brain signalling: neuropsychopharmacological implications,” Pharmacology & Therapeutics, vol. 130, pp. 26–238, 2011.
[26]
M. N. Silverman, C. M. Heim, U. M. Nater, A. H. Marques, and E. M. Sternberg, “Neuroendocrine and immune contributors to fatigue,” PM and R, vol. 2, no. 5, pp. 338–346, 2010.
[27]
L. Capuron, J. F. Gumnick, D. L. Musselman et al., “Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions,” Neuropsychopharmacology, vol. 26, no. 5, pp. 643–652, 2002.
[28]
L. Capuron and A. H. Miller, “Cytokines and psychopathology: lessons from interferon-α,” Biological Psychiatry, vol. 56, no. 11, pp. 819–824, 2004.
[29]
M. A. Moskowitz, E. H. Lo, and C. Iadecola, “The science of stroke: mechanisms in search of treatments,” Neuron, vol. 67, no. 2, pp. 181–198, 2010.
[30]
S. C. Tang, T. V. Arumugam, X. Xu et al., “Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 34, pp. 13798–13803, 2007.
[31]
E. Okun, K. J. Griffioen, and M. P. Mattson, “Toll-like receptor signalling in neural plastcity and disease,” Trends in Neurosciences, vol. 34, no. 5, pp. 269–281, 2011.
[32]
T. E. Foley and M. Fleshner, “Neuroplasticity of dopamine circuits after exercise: implications for central fatigue,” NeuroMolecular Medicine, vol. 10, no. 2, pp. 67–80, 2008.
[33]
R. Meeusen, P. Watson, H. Hasegawa, B. Roelands, and M. F. Piacentini, “Central fatigue: the serotonin hypothesis and beyond,” Sports Medicine, vol. 36, no. 10, pp. 881–909, 2006.
[34]
L. Ronnback and E. Hansson, “On the potential role of glutamate transport in mental fatgiue,” Journal of Neuroinflammation, vol. 1, article 22, 2004.
[35]
S. L. Patterson, T. Abel, T. A. S. Deuel, K. C. Martin, J. C. Rose, and E. R. Kandel, “Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice,” Neuron, vol. 16, no. 6, pp. 1137–1145, 1996.
[36]
D. J. Clauw and G. P. Chrousos, “Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms,” NeuroImmunoModulation, vol. 4, no. 3, pp. 134–153, 1998.
[37]
R. Schondorf, J. Benoit, T. Wein, and D. Phaneuf, “Orthostatic intolerance in the chronic fatigue syndrome,” Journal of the Autonomic Nervous System, vol. 75, no. 2-3, pp. 192–201, 1999.
[38]
J. E. Bower, P. A. Ganz, L. T. May et al., “Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer,” Clinical Cancer Research, vol. 15, no. 17, pp. 5534–5540, 2009.
[39]
C. J. Smith, H. C. A. Emsley, C. M. Gavin et al., “Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome,” BMC Neurology, vol. 4, article 2, 2004.
[40]
C. L. Raison, J. M. S. Lin, and W. C. Reeves, “Association of peripheral inflammatory markers with chronic fatigue in a population-based sample,” Brain, Behavior, and Immunity, vol. 23, no. 3, pp. 327–337, 2009.
[41]
J. Gaab, N. Rohleder, V. Heitz et al., “Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome,” Psychoneuroendocrinology, vol. 30, no. 2, pp. 188–198, 2005.
[42]
J. M. Annoni, F. Staub, J. Bogousslavsky, and A. Brioschi, “Frequency, characterisation and therapies of fatigue after stroke,” Neurological Sciences, vol. 29, no. 2, pp. S244–S246, 2008.
[43]
C. Y. Hsu, M. Vennelle, H. Y. Li, H. M. Engleman, M. S. Dennis, and N. J. Douglas, “Sleep-disordered breathing after stroke: a randomised controlled trial of continuous positive airway pressure,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 10, pp. 1143–1149, 2006.
[44]
E. McGeough, A. Pollock, L. N. Smith et al., “Interventions for post-stroke fatigue,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD007030, 2009.
[45]
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy), National Institutue for Clinical Excellence, 2007.
[46]
S. J. Lewis, A. J. Barugh, C. A. Greig, D. H. Saunders, C. Fitzsimons, and S. Dinan-Young, “Is fatigue after stroke associated with physical deconditioning? A cross-sectional study in ambulatory stroke survivors,” Archives of Physical Medicine and Rehabilitation, vol. 92, pp. 295–298, 2011.
[47]
M. J. MacKay-Lyons and L. Makrides, “Exercise capacity early after stroke,” Archives of Physical Medicine and Rehabilitation, vol. 83, no. 12, pp. 1697–1702, 2002.
[48]
E. Blomstrand, “A role for branched-chain amino acids in reducing central fatigue,” Journal of Nutrition, vol. 136, no. 2, pp. S544–S547, 2006.
[49]
E. J. Sanchez-Barcelo, M. D. Mediavilla, D. X. Tan, and R. J. Reiter, “Clinical uses of melatonin: evaluation of human trials,” Current Medicinal Chemistry, vol. 17, no. 19, pp. 2070–2095, 2010.
[50]
H. C. A. Emsley, C. J. Smith, R. F. Georgiou et al., “A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 10, pp. 1366–1372, 2005.
[51]
N. Rothwell, “Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential,” Brain, Behavior, and Immunity, vol. 17, no. 3, pp. 152–157, 2003.
[52]
B. V. Zlokovic and J. H. Griffin, “Cytoprotective protein C pathways and implications for stroke and neurological disorders,” Trends in Neurosciences, vol. 34, no. 4, pp. 198–209, 2011.
[53]
D. E. Joyce and B. W. Grinnell, “Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κB,” Critical Care Medicine, vol. 30, no. 5, pp. S288–S293, 2002.
